Agilent Technologies Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Direxion Daily FTSE China Bull 3x Shares trades at $29.06. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| A | YINN | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $56.62 |
52-Week Low | $110.24 | $21.45 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $31.50, up 1.68% with a bullish technical signal. The ETF tracks Chinese equities, showing strength amid Hang Seng Index outperformance versus Asian peers. Moving averages signal bullish momentum while oscillators remain neutral. Recent news highlights China's AI investment plans and export growth, though regulatory tensions with the US persist.
Outlook remains cautiously optimistic given China's tech focus and infrastructure spending, but leveraged structure amplifies risks. Key risks include US-China trade tensions and China's economic stabilization efforts. Investors should weigh the ETF's 3x leverage against China's growth trajectory and regulatory environment.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →